Brad Wood, M.D.
Bradford Wood is an Adjunct Investigator in the Office of the Clinical Director, CCR. Dr. Wood is Director of the NIH Center for Interventional Oncology and Chief of Interventional Radiology. He directs a multidisciplinary team within a collaborative environment focused on first-in-human clinical translational research and development with academic, industry, and government components.
Dr. Wood's translational research interests include fusion and navigation tools, minimally invasive and image-guided tumor ablation tools and treatment planning, drug plus device combination therapies, heat-deployed nanoparticles activated with needles or ultrasound, GPS-enabled medical and surgical devices, image-able drugs (drug eluting beads and liposomes), image-guided robotics, and HIFU for non-invasive ablation or "drug paint-brushing" of chemotherapy.
Dr. Wood directs a multidisciplinary team of scientists, students, research nurses, biomedical engineers, computer scientists, chemists, technologists, and physician-scientists within a collaborative environment focused on first in human clinical translational research and development with academic, industry, and government components.
His translational research interests include fusion and navigation tools, minimally-invasive and image-guided tumor ablation tools and treatment planning, drug plus device combination therapies, heat-deployed nanoparticles activated with needles or ultrasound GPS-enabled medical and surgical devices, image-able drugs (drug-eluting beads and liposomes), image-guided robotics, and HIFU for non-invasive ablation or "drug paint-brushing" of chemotherapy.
Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.Urol Oncol. [Epub ahead of print - Aug. 7], 2015. [ Journal Article ]
- Cardiovasc Intervent Radiol. [Epub ahead of print - Aug. 6], 2015. [ Journal Article ]
- Abdom Imaging. [Epub ahead of print - Aug. 4], 2015. [ Journal Article ]
Direct Quantification and Comparison of Intratumoral Hypoxia following Transcatheter Arterial Embolization of VX2 Liver Tumors with Different Diameter Microspheres .J Vasc Interv Radiol. [Epub ahead of print - Jul. 28], 2015. [ Journal Article ]
Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors .Cardiovasc Intervent Radiol. [Epub ahead of print - Jul. 31], 2015. [ Journal Article ]
Bradford Wood earned both his undergraduate and graduate degrees from The University of Virginia, then completed an Internship in internal medicine, followed by a residency in diagnostic radiology at Georgetown University, where he was Chief Resident. He then went on to complete double fellowships at Massachusetts General Hospital at Harvard in abdominal imaging and intervention and vascular and interventional radiology, and stayed on staff at Massachusetts General Hospital/Harvard after training. Dr. Wood is board-certified in vascular and interventional radiology as well as diagnostic radiology.
Dr. Wood has practiced interventional radiology at the NIH since 1998, when he was recruited from Harvard/Massachusetts General Hospital. He has directed the Interventional Radiology Research Lab from 2004 to present, and was Acting Chief of Radiology - Science and Research and Acting Director of the Molecular Imaging Lab from 2006 to 2008. Dr. Wood holds appointments in several NIH institutes and centers, including the NIH Clinical Center and the National Cancer Institute and is credentialed in surgery and radiology. He has received both the NIH Clinical Center Director's Award and the NIH Director's Award, and has published widely in the field of interventional radiology and the emerging discipline of interventional 0ncology.
His scientific achievements include multiple patents in the field, and pioneering several technologies from the bench to the patient, now in widespread use, including heat-deployed chemotherapy combined with thermal ablation for liver cancer, “medical GPS” electromagnetic (EM) tracking for needle-based procedures like biopsy and thermal ablation, and smart needles and devices for minimally invasive, multi-modality, image-guided procedures.
He postulated and implemented bench-to-bedside Phase I trials of radiofrequency ablation for liver tumors, augmented with heat-deployed chemotherapy (heat-sensitive liposomal doxorubicin), which is currently post Phase III for hepatocellular carcinoma.
He was among the first physicians to perform radiofrequency ablation for kidney and liver tumors in humans in the mid-1990s, to use ablation devices plus heat-deployed drugs for liver tumors, to guide ablation and biopsy with "GPS-enabled" devices, to combine MRI and ultrasound for fusion-guided prostate biopsy, "medical GPS" fusion-guided ablation and biopsy, and RF ablation for patients with pheochromocytoma, lymphoma, adrenocortical carcinoma, liver abscess, chordoma, and intractable hematuria.
In the 2000s, NIH teams also deployed percutaneous methods for isolated liver perfusion (chemosaturation) for regional liver therapy. NIH teams have performed over 12,000 needle procedures in more than 850 patients with the tracking/fusion technology.
Dr. Wood has published extensively in the field, coauthoring a book on radiology, more than 200 manuscripts and chapters, hundreds of scientific abstracts, and numerous patents or patent applications.